[Skip to Navigation]
Comment & Response
December 2018

High-Density Lipoprotein–Targeted Therapies—Not Dead Yet

Author Affiliations
  • 1Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York
JAMA Cardiol. 2018;3(12):1254-1255. doi:10.1001/jamacardio.2018.3962

To the Editor The authors of the MDCO-216 Infusions Leading to Changes in Atherosclerosis: a Novel Therapy in Development to Improve Cardiovascular Outcomes—Proof of Concept IVUS, Lipids, and Other Surrogate Biomarkers (MILANO-PILOT) trial1 conclude that there is an uncertainty regarding the therapeutic potential of targeting high-density lipoprotein (HDL). Although we concur that recent studies have not demonstrated positive outcomes with HDL-targeted therapies, this skepticism should not be based on data from this MILANO-PILOT trial.1

Add or change institution